JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leoncini, M.
Right arrow Articles by Pupi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leoncini, M.
Right arrow Articles by Pupi, A.
Journal of Nuclear Medicine Vol. 45 No. 5 739-744
© 2004 by Society of Nuclear Medicine


Clinical Investigations

Gated SPECT Evaluation of the Relationship Between Admission Troponin I, Myocardial Salvage, and Functional Recovery in Acute Myocardial Infarction Treated by Abciximab and Early Primary Angioplasty

Mario Leoncini, MD1, Francesco Bellandi, MD1, Roberto Sciagrà, MD2, Mauro Maioli, MD1, Anna Toso, MD1, Angela Coppola, MD3, Stelvio Sestini, MD3, Alberto Mennuti, MD3, Roberto Piero Dabizzi, MD1 and Alberto Pupi, MD2

1 Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy
2 Nuclear Medicine Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy
3 Nuclear Medicine Unit, Misericordia e Dolce Hospital, Prato, Italy

Using gated SPECT, we evaluated the relationship between admission troponin I, risk area, and myocardial salvage in patients with a first myocardial infarction treated with abciximab and primary percutaneous coronary intervention within 6 h. Methods: In 43 patients, 99mTc-sestamibi was injected before primary percutaneous coronary intervention. Gated SPECT was acquired immediately thereafter and was repeated 7 and 30 d later. The initial risk area and subsequent infarct size were expressed as a percentage of the left ventricle; salvage index was the ratio between salvaged myocardium and initial risk area; left ventricular ejection fraction was calculated using the quantitative gated SPECT software. Results: On admission, 20 patients showed elevated troponin I and had a larger risk area (P < 0.03) than did the group with normal troponin I. Infarct size at 30 d (15% ± 12% vs. 13% ± 13%) and salvage index (0.63 ± 0.27 vs. 0.60 ± 0.28) were not significantly different between the 2 groups. Ejection fraction was lower in the group with high troponin I on admission (36% ± 10% vs. 41% ± 11%, P < 0.05) and at 7 d (41% ± 11% vs. 48 ± 10, P < 0.03). At 30 d, improvement was greater in the group with high troponin I, and ejection fraction became comparable. Conclusion: Patients with high troponin I on admission have a larger initial risk area, but if they undergo primary percutaneous coronary intervention within 6 h and are treated with abciximab, myocardial salvage and functional recovery are similar to those observed in patients with normal troponin I, and no unfavorable relationship between high troponin I values on admission and myocardial salvage is registered.

Key Words: abciximab • gated SPECT • myocardial infarction • percutaneous coronary intervention • troponin




This article has been cited by other articles:


Home page
J Am Coll Cardiol IntvHome page
S. Chia, F. Senatore, O. C. Raffel, H. Lee, F. J. Th. Wackers, and I.-K. Jang
Utility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
J. Am. Coll. Cardiol. Intv., August 1, 2008; 1(4): 415 - 423.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.